Get the Stockscreener App
7.47
1.36%
0.10
After Hours:
7.42
-0.05
-0.67%
Precision Biosciences Inc stock is traded at $7.47, with a volume of 124.17K.
It is up +1.36% in the last 24 hours and up +2.61% over the past month.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
See More
Previous Close:
$7.37
Open:
$7.32
24h Volume:
124.17K
Relative Volume:
0.31
Market Cap:
$206.18M
Revenue:
$45.07M
Net Income/Loss:
$-44.49M
P/E Ratio:
-2.0102
EPS:
-3.716
Net Cash Flow:
$-54.23M
1W Performance:
-3.98%
1M Performance:
+2.61%
6M Performance:
+56.60%
1Y Performance:
+48.51%
1-Day Range:
$7.32
$7.575
1-Week Range:
$7.23
$7.82
52-Week Range:
$3.53
$9.62
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
7.47 | 240.69M | 45.07M | -44.49M | -54.23M | -3.716 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Behavioral Patterns of DTIL and Institutional Flows - news.stocktradersdaily.com
Precision BioSciences stock gains as market cap tops 200 million USD - AD HOC NEWS
Precision Biosciences Stock Price Forecast. Should You Buy DTIL? - StockInvest.us
Precision BioSciences Inc. (DTIL) Key Financial Ratios – Valuation, Profitability & More - Value Research
Precision BioSciences Inc. (DTIL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Precision BioSciences doses first patient in DMD gene editing trial By Investing.com - Investing.com Canada
Precision BioSciences doses first patient in DMD gene editing trial - Investing.com
Precision (DTIL) Range: Posts a 2.59% Gain to $8.72 at the Close; the Current Price Sits Inside the Supplied Technical Range in the Latest ReadingLiquidity Order Flow - vinanet.vn
DTIL Looks 355.6% Overvalued on GF Value™ - GuruFocus
Precision BioSciences: Promising HBV Editing Evidence (NASDAQ:DTIL) - Seeking Alpha
Precision BioSciences Inc (DTIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Precision BioSciences Inc Stock Intrinsic Values - GuruFocus
Precision BioSciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Competitors 2026 - GuruFocus
Precision BioSciences Inc Stock Warning Signs | HAM:PBS0 - GuruFocus
Who's Buying or Selling Precision BioSciences Inc (HAM:PBS0) Stock Today? - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Price & 30 Year Financial Data - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Earnings Transcripts - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
HAM:PBS0 Dividend: Does Precision BioSciences Inc Pay a Dividend? - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Price, Trades & News - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock News, Headlines & Updates - GuruFocus
Precision BioSciences (DTIL) Rises 1.78% as Gene-Editing Stock Holds Firm Above SupportGrowth Stock Picks - vinanet.vn
Precision BioSciences (DTIL) Advances 1.78% as Gene-Editing Speculation BuildsBear Flag - Vinanet
Precision BioSciences Inc (DTIL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts Have Lowered Expectations For Precision BioSciences, Inc. (NASDAQ:DTIL) After Its Latest Results - webull.com
Precision BioSciences (NASDAQ:DTIL) Announces Quarterly Earnings Results - MarketBeat
Precision BioSciences (NASDAQ:DTIL) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Precision BioSciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Precision Trading with Precision Biosciences Inc. (DTIL) Risk Zones - Stock Traders Daily
Precision BioSciences, Inc. (DTIL) stock price, news, quote and history - Yahoo Finance Singapore
DTIL Looks 315.0% Overvalued on GF Value™ - GuruFocus
Form 8K Precision BioSciences Inc For: 6 August By Investing.com - Investing.com Nigeria
Precision BioSciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Precision BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Precision BioSciences Q2 net loss widens on warrant liability charge - TradingView
Precision BioSciences reports Q2 2026 net loss $32.7M; $112.4M cash supports runway through 2028 - TradingView
PRECISION BIOSCIENCES INC Q2 2026: Revenue $0 EPS $(1.26) — 10-Q Summary - tradingview.com
Precision BioSciences (NASDAQ: DTIL) books $10.8M H1 revenue and advances gene editing trials - Stock Titan
Precision Biosciences 2Q Loss/Shr $1.26 >DTIL - moomoo.com
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Q2 EPS Forecast for Precision BioSciences Lowered by Analyst - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For Precision BioSciences, Inc. (NASDAQ:DTIL) - webull.com
Precision BioSciences Inc expected to post a loss of 79 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL) - The Globe and Mail
Precision BioSciences (DTIL) Climbs 3.12% to $7.28 as Gene-Editing Support HoldsChange of Character - dars.gov.et
H.C. Wainwright reiterates Precision BioSciences stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Precision BioSciences stock rating at buy - Investing.com
Weekly Recap: Q2 2026 report date confirmed and COO and CFO appointments - TradingView
Precision Biosciences (DTIL) officer details stock and RSU holdings - Stock Titan
H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):